Focus on strategic brands paying off for Lundbeck

11 May 2022

Shares of Denmark-based CNS specialist Lundbeck (LUND: CO) were up 7% at 161.30 Danish kroner in early afternoon trading, after it released a strong set of first-quarter 2022 financials.

Total revenue reached 4,372 million kroner ($621.9 million) in the quarter, an increase of 2%, as the quarter was impacted by lower revenue of Northera (droxidopa) following its loss of exclusivity in the first quarter of 2021 while also benefitting from appreciation of main currencies.

In aggregate, strategic brands grew 25% in the first quarter of 2022 reaching 2,668 million kroner or 61% of total revenue.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK